Shockwave Medical and CRISPR Therapeutics Beat Expectations in Q1 Earnings, Ocular Therapeutix Falls Short
- May 08th, 2023
- 367 views
Shockwave Medical, Inc. (Nasdaq: SWAV) reported better-than-expected Q1 earnings, with an EPS of $1.03 versus the consensus estimate of $0.81. In after-hours trading, SWAV is up $10.04 (+3.65%) and is currently trading at $285.00.
On the other hand, CRISPR Therapeutics AG (Nasdaq: CRSP) reported a Q1 loss of $0.67 per share, which was better than the consensus estimate of a loss of $1.70 per share. As a result, in after-hours trading, CRSP is up $0.54 (+0.96%) and is currently trading at $56.50.
Finally, Ocular Therapeutix, Inc. (Nasdaq: OCUL) reported a Q1 loss of $0.39 per share, worse than the consensus estimate of a loss of $0.26 per share. As a result, in after-hours trading, OCUL is down $0.30 (-4.69%) and is currently trading at $6.10.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024Key Metrics: CyberArk Software, Hudbay Minerals, and Sonos Earnings Due
November 11th, 2024Earnings: What to Expect from Occidental Petroleum, Rocket Lab, and CAE
November 10th, 2024Earnings Countdown: Home Depot, Sea Limited, and Natera in the Spotlight
November 10th, 2024Ahead of Earnings: DoorDash, MetLife, and Exelon in the Spotlight
October 27th, 2024
Member Login